Cargando…

5α-reductase inhibitors impact prognosis of urothelial carcinoma

BACKGROUND: 5α-reductase inhibitors (5-ARIs) inhibit the pathway of converting the testosterone to dihydrotestosterone and are widely used in benign prostatic hyperplasia patients. Since androgen receptor activation may play a role in urothelial tumorigenesis, we conducted this retrospective cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chien-Sheng, Li, Ching-Chia, Juan, Yung-Shun, Wu, Wen-Jeng, Lee, Hsiang-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488389/
https://www.ncbi.nlm.nih.gov/pubmed/32917158
http://dx.doi.org/10.1186/s12885-020-07373-4
_version_ 1783581679368011776
author Wang, Chien-Sheng
Li, Ching-Chia
Juan, Yung-Shun
Wu, Wen-Jeng
Lee, Hsiang-Ying
author_facet Wang, Chien-Sheng
Li, Ching-Chia
Juan, Yung-Shun
Wu, Wen-Jeng
Lee, Hsiang-Ying
author_sort Wang, Chien-Sheng
collection PubMed
description BACKGROUND: 5α-reductase inhibitors (5-ARIs) inhibit the pathway of converting the testosterone to dihydrotestosterone and are widely used in benign prostatic hyperplasia patients. Since androgen receptor activation may play a role in urothelial tumorigenesis, we conducted this retrospective cohort study to determine whether 5α-reductase inhibitors (5-ARIs) administration is associated with bladder cancer mortality, bladder cancer recurrence and upper tract urothelial carcinoma mortality, using the Taiwan National Health Insurance database. METHODS: The data of this retrospective cohort study were sourced from the Longitudinal Health Insurance Database of Taiwan, compiled by the Taiwan National Health Insurance database from 1996 to 2010. It consists of 18,530 men with bladder cancer, of whom 474 were 5-ARIs recipients and 4384 men with upper tract urothelial carcinoma, of whom 109 were 5-ARIs recipients. Propensity Score Matching on the age and geographic data was done at the ratio of 1:10. We analyzed the odds ratios (OR) and 95% confidence interval (CI) of the risk of bladder cancer death, bladder cancer recurrence rate and upper tract urothelial carcinoma related death by the 5-ARIs administration. RESULTS: Those who received 5-ARIs showed a lower risk of bladder cancer related death compared to nonusers in multivariable adjusted analysis (OR 0.835, 95% CI 0.71–0.98). However, there was no significant difference in the bladder cancer recurrence rate (OR 0.956, 95% CI 0.82–1.11) and upper tract urothelial carcinoma related mortality in multivariable adjusted analysis (OR 0.814, 95% CI 0.6–1.1). CONCLUSIONS: Patients who receive 5-ARIs have lower bladder cancer related mortality compared to those who don’t. 5-ARIs may prove to be a viable strategy to improve bladder cancer outcomes.
format Online
Article
Text
id pubmed-7488389
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74883892020-09-16 5α-reductase inhibitors impact prognosis of urothelial carcinoma Wang, Chien-Sheng Li, Ching-Chia Juan, Yung-Shun Wu, Wen-Jeng Lee, Hsiang-Ying BMC Cancer Research Article BACKGROUND: 5α-reductase inhibitors (5-ARIs) inhibit the pathway of converting the testosterone to dihydrotestosterone and are widely used in benign prostatic hyperplasia patients. Since androgen receptor activation may play a role in urothelial tumorigenesis, we conducted this retrospective cohort study to determine whether 5α-reductase inhibitors (5-ARIs) administration is associated with bladder cancer mortality, bladder cancer recurrence and upper tract urothelial carcinoma mortality, using the Taiwan National Health Insurance database. METHODS: The data of this retrospective cohort study were sourced from the Longitudinal Health Insurance Database of Taiwan, compiled by the Taiwan National Health Insurance database from 1996 to 2010. It consists of 18,530 men with bladder cancer, of whom 474 were 5-ARIs recipients and 4384 men with upper tract urothelial carcinoma, of whom 109 were 5-ARIs recipients. Propensity Score Matching on the age and geographic data was done at the ratio of 1:10. We analyzed the odds ratios (OR) and 95% confidence interval (CI) of the risk of bladder cancer death, bladder cancer recurrence rate and upper tract urothelial carcinoma related death by the 5-ARIs administration. RESULTS: Those who received 5-ARIs showed a lower risk of bladder cancer related death compared to nonusers in multivariable adjusted analysis (OR 0.835, 95% CI 0.71–0.98). However, there was no significant difference in the bladder cancer recurrence rate (OR 0.956, 95% CI 0.82–1.11) and upper tract urothelial carcinoma related mortality in multivariable adjusted analysis (OR 0.814, 95% CI 0.6–1.1). CONCLUSIONS: Patients who receive 5-ARIs have lower bladder cancer related mortality compared to those who don’t. 5-ARIs may prove to be a viable strategy to improve bladder cancer outcomes. BioMed Central 2020-09-11 /pmc/articles/PMC7488389/ /pubmed/32917158 http://dx.doi.org/10.1186/s12885-020-07373-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Wang, Chien-Sheng
Li, Ching-Chia
Juan, Yung-Shun
Wu, Wen-Jeng
Lee, Hsiang-Ying
5α-reductase inhibitors impact prognosis of urothelial carcinoma
title 5α-reductase inhibitors impact prognosis of urothelial carcinoma
title_full 5α-reductase inhibitors impact prognosis of urothelial carcinoma
title_fullStr 5α-reductase inhibitors impact prognosis of urothelial carcinoma
title_full_unstemmed 5α-reductase inhibitors impact prognosis of urothelial carcinoma
title_short 5α-reductase inhibitors impact prognosis of urothelial carcinoma
title_sort 5α-reductase inhibitors impact prognosis of urothelial carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488389/
https://www.ncbi.nlm.nih.gov/pubmed/32917158
http://dx.doi.org/10.1186/s12885-020-07373-4
work_keys_str_mv AT wangchiensheng 5areductaseinhibitorsimpactprognosisofurothelialcarcinoma
AT lichingchia 5areductaseinhibitorsimpactprognosisofurothelialcarcinoma
AT juanyungshun 5areductaseinhibitorsimpactprognosisofurothelialcarcinoma
AT wuwenjeng 5areductaseinhibitorsimpactprognosisofurothelialcarcinoma
AT leehsiangying 5areductaseinhibitorsimpactprognosisofurothelialcarcinoma